You are here

Article Text

Article menu
Download PDFPDF
Editorial
Molnupiravir: evidence by press release
  1. James A Cave1,
  2. David Phizackerley2
  1. 1 The Downland Practice, Berkshire, UK
  2. 2 DTB, BMJ Journals, London, UK
  1. Correspondence to Dr James A Cave, The Downland Practice, Berkshire RG20 8UY, UK; jcave{at}bmj.com

https://doi.org/10.1136/dtb.2021.000064

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    On 4 November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that it had approved molnupiravir (▼Lagevrio) as the first oral antiviral drug authorised for COVID-19.1 In its press release, the MHRA chief executive was quoted as saying, “Lagevrio is another therapeutic to add to our armoury against COVID-19. It is also the world’s first approved antiviral for this disease that can be taken by mouth rather than administered intravenously.” Shortly before 11am on the same day, the Secretary for State for Health and Social Care posted a video on social media extolling the benefits of molnupiravir, suggesting “in clinical trials this treatment has been shown to reduce the risk of hospitalisation or death for COVID-19 patients who are most at risk by 50%.”2

    Molnupiravir is indicated for treatment of mild to …

    View Full Text

    Footnotes

    • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

    • Provenance and peer review Commissioned; externally peer reviewed.